Artrya (AYA) Q1 2027 earnings summary

Executive summary

• U.S. commercial execution advanced with Huntsville Hospital Health System, the largest customer to date, signing a five-year agreement after SAPPHIRE participation—the study’s first commercial conversion.

• Tanner’s Coronary Plaque use rose materially after a mid-September pre-authorization workflow change; higher activity continued into October.

• Coronary Flow filing timing extended after reader inconsistencies prompted an additional evidence study; the study was not requested by the FDA.

Financial highlights

• Customer receipts were A$84,000, including subscriptions from Tanner and Northeast Georgia and Tanner per-scan revenue.

• Operating costs excluding interest income were AUD 7.3m; costs excluding the R&D rebate and interest income were A$7.4M, versus A$6.5M in the prior quarter on that basis.

• Net cash outflow was A$6.9M, including A$6.824M net operating cash outflow; interest receipts were A$0.5M.

• Cash and term deposits totaled A$67.2M at September 30, 2026; the A$4.8M FY2026 R&D rebate claim was expected to be lodged in October, with receipt estimated in early 2027.

Outlook and guidance

• Huntsville implementation across 15 hospitals and 19 heart centres involves PACS and IT integration, workflow training and reimbursement pathways.

• Northeast Georgia’s rollout beyond its main campus was well advanced; Cone Health’s clinical and IT implementation remains a near-term priority following delays tied to its Kaiser Permanente transition.

• A further reader study will strengthen the Coronary Flow 510(k) submission; filing and clearance timing was extended, with an update planned upon filing.

• Prior foundation-customer exit run-rate reference was 15,000 CCTA scans; Huntsville implementation before FY27 year-end could lift the run rate to 22,000–23,000 scans entering the next financial year.